Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoliflodacin TQT Study
NCT03613649Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Sep 2018
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of zoliflodacin in gonorrhea (4 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Placebo-corrected, Baseline-adjusted Mean QTcF Interval at 24 hours. Started Sep 2018; status: completed.
02
Drugs
zoliflodacin
03
Conditions
gonorrhea
Beyond the preview
Go deeper on NCT03613649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03613649.